Physician profile
Ryan D Hollenbeck
NPI 1689878175
$19,144.76
in general payments reported to CMS, 2019-2025
32 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $219 · 2021: $483 · 2022: $1,172 · 2023: $815 · 2024: $2,731 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $14K · Food and Beverage: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,593.78 |
| Food and Beverage | $2,756.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15,834.59 | 2021-2025 | Corevalve Evolut R, In.Pact Admiral, Mvp |
| Edwards Lifesciences Corporation | $418.16 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $412.03 | 2019-2025 | Optis, Diamondback Coronary, Xience Skypoint |
| Novartis Pharmaceuticals Corporation | $380.67 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $344.97 | 2019-2024 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $278.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $210.32 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $173.93 | 2019-2025 | Enroute Transcarotid Stent, General - Therapies |
| Pfizer INC. | $163.21 | 2019-2025 | |
| Amgen INC. | $96.45 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $83.83 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $71.87 | 2020-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.97 | 2019-2023 | Jardiance |
| Abiomed | $63.83 | 2021-2023 | Impella |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $59.06 | 2020 | |
| Amarin Pharma, INC. | $54.33 | 2020-2021 | |
| Lantheus Medical Imaging, INC. | $50.16 | 2023 | Definity |
| Cardiovascular Systems INC. | $37.40 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $33.37 | 2022 | |
| Teleflex LLC | $32.69 | 2019-2024 | Supercross |
| Regeneron Healthcare Solutions, INC. | $32.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.58 | 2022 | |
| Bridgebio Pharma, INC. | $21.43 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $19.36 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $18.74 | 2022 | |
| Siemens Medical Solutions USA, INC. | $16.86 | 2019 | |
| Novo Nordisk INC | $14.71 | 2025 | Wegovy |
| Bard Peripheral Vascular, INC. | $14.02 | 2021 | |
| Philips North America LLC | $13.67 | 2019 | |
| Shockwave Medical, INC | $12.99 | 2022 | |
| Esperion Therapeutics, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hollenbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.